| Literature DB >> 24603860 |
Maroya Spalding Walters1, Janell Routh1, Matthew Mikoleit2, Samuel Kadivane3, Caroline Ouma4, Denis Mubiru5, Ben Mbusa6, Amos Murangi7, Emmanuel Ejoku8, Absalom Rwantangle9, Uziah Kule10, John Lule11, Nancy Garrett2, Jessica Halpin2, Nikki Maxwell2, Atek Kagirita5, Fred Mulabya12, Issa Makumbi12, Molly Freeman2, Kevin Joyce2, Vince Hill2, Robert Downing11, Eric Mintz2.
Abstract
BACKGROUND: Salmonella enterica serovar Typhi is transmitted by fecally contaminated food and water and causes approximately 22 million typhoid fever infections worldwide each year. Most cases occur in developing countries, where approximately 4% of patients develop intestinal perforation (IP). In Kasese District, Uganda, a typhoid fever outbreak notable for a high IP rate began in 2008. We report that this outbreak continued through 2011, when it spread to the neighboring district of Bundibugyo. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2014 PMID: 24603860 PMCID: PMC3945727 DOI: 10.1371/journal.pntd.0002726
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Figure 1Map of Uganda showing affected districts.
Figure 2Typhoid fever cases by month of illness onset and intestinal perforation status.
(A) Kasese District, August 1, 2009–December 31, 2011, n = 695 with known or estimated onset date and known intestinal perforation status (B) Bundibugyo District, January 1–December 31, 2011, n = 293 with known or estimated onset date and known intestinal perforation status.
Demographic characteristics of patients with suspected or confirmed typhoid fever, Kasese and Bundibugyo districts, Uganda, August 1, 2009–December 31, 2011.
| Kasese | Bundibugyo | |||||||
| Characteristic | Intestinal Perforation (n = 570 | No Intestinal Perforation (n = 127 | All Patients |
| Intestinal Perforation (n = 59 | No Intestinal Perforation (n = 234 | All Patients |
|
|
| ||||||||
| All patients | 17 (<1–85) | 15.5 (1–70) | 17 (<1–85) | 12 (3–50) | 13 (1–68) | 13 (<1–68) | ||
| Females only | 14 (<1–85) | 16 (1–70) | 15 (<1–85) | 10 (3–50) | 18 (1–65) | 16 (1–65) | 0.008 | |
| Males only | 19 (2–80) | 13 (2–70) | 18 (2–80) | 0.02 | 15 (3–41) | 12 (2–68) | 12.5 (<1–68) | |
|
| ||||||||
| Male | 336 (59) | 55 (46) | 391 (57) | 0.01 | 39 (66) | 88 (40) | 142 (45) | <0.0001 |
*Includes 12 patients for whom intestinal perforation status was reported by clinician as “don't know”.
**Includes 7 patients for whom intestinal perforation status was reported by clinician as “don't know” and 33 patients for whom intestinal perforation status could not be determined from district linelist.
For some items, n may vary by small numbers due to “don't know” or missing responses.
Wilcoxon rank-sum test (median age) or Fisher's exact test (gender) for difference between Kasese patients with and without intestinal perforation.
Wilcoxon rank-sum test (median age) or Fisher's exact test (gender) for difference between Bundibugyo patients with and without intestinal perforation.
Median age different by gender among all Kasese patients (P = 0.002) and among patients with intestinal perforation from Kasese (P = 0.0004) and Bundibugyo (P = 0.03). Median age did not differ significantly by gender among patients without intestinal perforation in either district.
Figure 3Cases of typhoid fever in Bundibugyo, by age, gender, and intestinal perforation status.
January 1–December 31, 2011, n = 244 with known age, sex, and intestinal perforation status, *P = 0.03 and **P = 0.0006.
Clinical features*of typhoid fever patients reported on case report forms, Kasese and Bundibugyo Districts, April 15, 2011–December 31, 2011.
| No. (%) Kasese Patients (n = 149 | No. (%) Bundibugyo Patients (n = 128 | No. (%) All Patients (n = 277 | |
|
| |||
| Weakness | 130 (87) | 104 (81) | 234 (84) |
| Headache | 129 (87) | 97 (76) | 226 (82) |
| Joint Pain | 106 (72) | 88 (70) | 194 (71) |
| Diarrhea | 61 (41) | 50 (39) | 111 (40) |
| Not responding to antimalarials | 51 (35) | 42 (35) | 93 (35) |
| Vomiting | 52 (35) | 39 (31) | 91 (33) |
| Constipation | 29 (20) | 39 (31) | 68 (25) |
| Intestinal Perforation | 11 (8) | 4 (3) | 15 (6) |
*Case definition specified that fever and abdominal pain must be present.
For some items, n may vary by small numbers due to “don't know” responses.
Clinical history of typhoid fever patients, Kasese and Bundibugyo Districts, April 15, 2011–January 6, 2012.
| Characteristic | No. (%) Kasese Patients (n = 149 | No. (%) Bundibugyo Patients (n = 128 | No. (%) All Patients (n = 277 |
|
| 105 (74) | 83 (66) | 188 (70) |
| Sought care from: | n = 105 | n = 83 | n = 188 |
| Drug shop/Pharmacy | 51 (49) | 41 (49) | 92 (49) |
| Health center/Hospital | 50 (48) | 40 (48) | 90 (48) |
| Herbalist | 7 (7) | 6 (7) | 13 (7) |
| Traditional healer | 0 (0) | 1 (1) | 1 (1) |
| Other | 1 (1) | 5 (6) | 6 (3) |
|
| 60 (47) | 51 (44) | 111 (45) |
| Antibiotics taken: | n = 60 | n = 51 | n = 111 |
| Metronidazole | 21 (35) | 19 (37) | 40 (36) |
| Ciprofloxacin | 14 (23) | 16 (31) | 30 (27) |
| Co-trimoxazole | 17 (28) | 12 (24) | 29 (26) |
| Amoxicillin | 15 (25) | 12 (24) | 27 (24) |
| Chloramphenicol | 2 (3) | 3 (6) | 5 (5) |
| Other | 7 (12) | 4 (8) | 11 (10) |
| ≥2 antibiotics | 12 (20) | 14 (27) | 26 (23) |
|
| 74 (56) | 83 (70) | 157 (62) |
For some items, n may vary by small numbers due to “don't know” responses.
*Percentage totals may be >100%; respondents could select ≥1 source of care and antibiotic.
Kasese patients: 1 school nurse; Bundibugyo patients: 5 friend or relative.
Kasese patients: 1 each cephalexin, erythromycin, gentamycin, 4 unknown; Bundibugyo patients: 1 each ceftriaxone and doxycycline, 2 unknown.
Selected characteristics of patients with suspected typhoid fever, by intestinal perforation (IP) status, April 15, 2011–January 6, 2012.
| Characteristic | No. (%) With IP (n = 18 | No. (%) Without IP (n = 250 |
|
|
| |||
|
| 17 (100) | 166 (69) | 0.004 |
| Sought care from: | n = 17 | n = 166 | |
| Health center/Hospital | 15 (88) | 76 (46) | 0.0008 |
| Drug shop/Pharmacy | 5 (29) | 88 (48) | |
| Herbalist | 2 (12) | 11 (7) | |
|
| 12 (75) | 98 (44) | 0.02 |
| Antibiotics: | n = 12 | n = 98 | |
| Metronidazole | 6 (50) | 35 (36) | |
| Co-trimoxazole | 1 (8) | 29 (30) | |
| Ciprofloxacin | 4 (33) | 26 (27) | |
| Amoxicillin | 1 (8) | 26 (27) | |
| Chloramphenicol | 3 (25) | 1 (1) | 0.004 |
| Other | 3 (25) | 9 (9) | |
| ≥2 antibiotics | 7 (58) | 24 (24) | 0.04 |
|
| 10 (67) | 154 (62) | |
|
| 10 (71) | 76 (31) | 0.003 |
|
| |||
| Owned ≥2 household items | 10 (56) | 201 (80) | 0.02 |
| Owned ≥2 animals | 7 (39) | 86 (34) | |
| Percent unemployed | 0 (0) | 22 (9) |
*For some items, n may vary by small numbers due to “don't know” responses.
**Fisher's Exact test.
Percentage totals may be >100%; respondents could select ≥1 source of care and antibiotic.
Patients with intestinal perforation: 1 each ceftriaxone, gentamycin, and unspecified; patients without intestinal perforation: 1 each cephalexin, doxycycline, erythromycin, and gentamycin, and 5 unspecified.
Figure 4Diversity of PFGE patterns among Salmonella Typhi isolated from Kasese and Bundibugyo patients.
Each XbaI/BlnI PFGE pattern combination is represented by a different shading; pattern combinations designated by letter are shared across districts and/or years. Salmonella Typhi isolated from October 18–December 31, 2011 were from 13 Bundibugyo and 5 Kasese patients; among these, we observed 6 and 4 pattern combinations, respectively. Investigations in Kasese from March 4–April 17, 2009 yielded 33 Salmonella Typhi isolates, among these 13 pattern combinations were identified [6].